Literature DB >> 15075659

Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome.

Michael D'Angelica1, Murray F Brennan, Arief A Suriawinata, David Klimstra, Kevin C Conlon.   

Abstract

OBJECTIVE: To define the natural history of resected intraductal papillary mucinous neoplasms (IPMN) of the pancreas and to identify clinical and pathologic prognostic features. SUMMARY BACKGROUND DATA: IPMN of the pancreas is a recently described pancreatic tumor. Because of a limited number of cases, prognostic factors and the natural history of resected cases have not been well defined.
MATERIALS AND METHODS: A prospective pancreatic database was reviewed to identify patients with IPMN who were surgically managed. Pathologic re-review of each case was performed, and the clinicopathologic features were examined. Log rank and chi2 analysis were used to identify factors predictive of survival and recurrence.
RESULTS: Over a 17-year period, 63 patients were identified. One patient was unresectable, 6 (10%) underwent a total pancreatectomy, and 56 (89%) had a partial pancreatectomy. Invasive carcinoma was present in 30 patients (48%). Transection margins were involved with atypia or carcinoma in 32 patients (51%). The median follow-up for survivors was 38 months. Disease-specific 5- and 10-year survival were 75% and 60%, respectively. Significant predictors of poor outcome included presentation with elevated bilirubin, presence of invasive carcinoma, increasing size and percentage of invasive carcinoma, histologic type of invasive carcinoma, positive lymph nodes, and vascular invasion. The presence of atypia or carcinoma in situ at the ductal resection margin was not associated with a poor outcome.
CONCLUSIONS: Overall, IPMN has a favorable prognosis. Poor outcome in a subset of patients is largely the result of the presence, extent, and type of an invasive component, lymph node metastases, and vascular invasion.

Entities:  

Mesh:

Year:  2004        PMID: 15075659      PMCID: PMC1356240          DOI: 10.1097/01.sla.0000114132.47816.dd

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  19 in total

1.  Mucin-hypersecreting intraductal neoplasms of the pancreas: a precursor to cystic pancreatic malignancies.

Authors:  J A Madura; E A Wiebke; T J Howard; O W Cummings; M T Hull; S Sherman; G A Lehman
Journal:  Surgery       Date:  1997-10       Impact factor: 3.982

2.  Intraductal papillary tumors and mucinous cystic tumors of the pancreas: clinicopathologic study of 38 cases.

Authors:  N Fukushima; K Mukai; Y Kanai; T Hasebe; K Shimada; H Ozaki; T Kinoshita; T Kosuge
Journal:  Hum Pathol       Date:  1997-09       Impact factor: 3.466

3.  Intraductal neoplasms of the pancreas.

Authors:  L W Traverso; E A Peralta; J A Ryan; R A Kozarek
Journal:  Am J Surg       Date:  1998-05       Impact factor: 2.565

4.  Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity.

Authors:  J A Rivera; C Fernández-del Castillo; M Pins; C C Compton; K B Lewandrowski; D W Rattner; A L Warshaw
Journal:  Ann Surg       Date:  1997-06       Impact factor: 12.969

5.  Intraductal oncocytic papillary neoplasms of the pancreas.

Authors:  N V Adsay; C F Adair; C S Heffess; D S Klimstra
Journal:  Am J Surg Pathol       Date:  1996-08       Impact factor: 6.394

6.  Intraductal papillary mucinous tumours of the pancreas. Clinical and therapeutic issues in 32 patients.

Authors:  C Azar; J Van de Stadt; F Rickaert; M Devière; M Baize; G Klöppel; M Gelin; M Cremer
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

7.  Intraductal papillary mucinous tumors of the pancreas: imaging studies and treatment strategies.

Authors:  M Sugiyama; Y Atomi
Journal:  Ann Surg       Date:  1998-11       Impact factor: 12.969

8.  Intraductal papillary mucinous neoplasms of the pancreas associated with so-called "mucinous ductal ectasia". Histochemical and immunohistochemical analysis of 29 cases.

Authors:  E Nagai; T Ueki; K Chijiiwa; M Tanaka; M Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  1995-05       Impact factor: 6.394

9.  Mucin-hypersecreting tumors of the pancreas: assessing the grade of malignancy preoperatively.

Authors:  K Yamaguchi; Y Ogawa; K Chijiiwa; M Tanaka
Journal:  Am J Surg       Date:  1996-04       Impact factor: 2.565

10.  Pattern of recurrence after resection for intraductal papillary mucinous tumors of the pancreas.

Authors:  M Sho; Y Nakajima; H Kanehiro; M Hisanaga; K Nishio; M Nagao; N Ikeda; H Kanokogi; T Yamada; H Nakano
Journal:  World J Surg       Date:  1998-08       Impact factor: 3.352

View more
  97 in total

1.  Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.

Authors:  Olivier Turrini; Joshua A Waters; Thomas Schnelldorfer; Keith D Lillemoe; Constantin T Yiannoutsos; Michael B Farnell; Michael G Sarr; C Max Schmidt
Journal:  HPB (Oxford)       Date:  2010-09       Impact factor: 3.647

2.  Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation.

Authors:  Anne Couvelard; Alain Sauvanet; Reza Kianmanesh; Pascal Hammel; Nathalie Colnot; Philippe Lévy; Philippe Ruszniewski; Pierre Bedossa; Jacques Belghiti
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

3.  A new approach to managing intraductal papillary mucinous pancreatic neoplasms.

Authors:  Paula Ghaneh; John Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

4.  Natural History of Patients Followed Radiographically with Mucinous Cysts of the Pancreas.

Authors:  Linda M Pak; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Vinod P Balachandran; William R Jarnagin; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2017-05-17       Impact factor: 3.452

Review 5.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

6.  The clinicopathologic features of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Xinyu Qin; Fenglin Liu
Journal:  Front Med China       Date:  2007-02-01

7.  An analysis of clinico-pathologic features of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Wenhui Lou; Dayong Jin; Dansong Wang; Xuefeng Xu; Tiantao Kuang; Xinyu Qin
Journal:  Front Med China       Date:  2007-02-01

8.  Natural History and Treatment Trends in Pancreatic Cancer Subtypes.

Authors:  Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

9.  Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Seung-Mo Hong; David Kelly; Margaret Griffith; Noriyuki Omura; Ang Li; Chung-Pin Li; Ralph H Hruban; Michael Goggins
Journal:  Mod Pathol       Date:  2008-09-26       Impact factor: 7.842

10.  PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Helen E Remotti; Werner Hohenberger; Gloria H Su
Journal:  Langenbecks Arch Surg       Date:  2008-02-21       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.